Key facts
- It has raised $7.6M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Qiming Venture Partners, CICC Capital, China Capital Management, SAIF Partners, Suzhou Wuzhong Jinkong Equity Investment Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Prcxi
- ·The full record, as it builds
Funding rounds
No funding rounds for Prcxi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prcxi
Developer of instruments and reagents designed for life sciences and biopharmaceuticals. The company's products offer automation and solutions in the fields of life sciences and biopharmaceuticals, forensic medicine, clinical diagnosis, public health, epidemic prevention, and food quality and safety, covering instruments, reagents, consumables, software, and services, enabling customers to get more accurate results earlier.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2014
- Employees
- 300
- Website
- prcxi.com/
- Ownership
- Privately Held (backing)
Prcxi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prcxi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prcxi in its N-PORT filings yet. We sweep new filings monthly.